Related Experiment Video
Updated: Jul 9, 2026

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial
A R Sheon1, L Wagner, M J McElrath
1Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA. ASheon@umich.edu
Context:
Preventive HIV vaccines can temporarily cause uninfected individuals to have positive results on HIV testing. As preparations are underway to mount larger efficacy trials, the social risks of trial participation should be studied.
Objective:
To describe frequency of HIV testing and discrimination among participants in a preventive phase II HIV vaccine trial.
Participants:
266 vaccine trial volunteers were eligible; 247 participated in a confidential survey.
Results:
63 volunteers (26% of respondents) reported 185 HIV tests during the prior 12 to 24 months; most tests were for other research studies, health care, insurance, incarceration, or employment. Only 5 volunteers reported having positive HIV test results. Volunteers reported 99 adverse social incidents or problems, 53 of which were related to the trial. The most common type of event occurred when volunteers disclosed their trial participation and were mistakenly presumed to be infected with HIV. Few reported difficulty obtaining insurance, job loss, and inadvertent disclosure of their participation in the trial.
Conclusion:
In this vaccine trial, few serious social harms were reported. Those who conduct HIV tests for insurance, employment, health care, or other reasons should be made aware that HIV vaccines can cause false-positive HIV test results. Those planning future trials must continue to provide needed support to volunteers. Social harms should be monitored with the same vigilance accorded to physical harms.
More Related Videos
09:26In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
Published on: October 15, 2013
14:23A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
Related Concept Videos
Ethics in Research
Clinical Trials
There are four phases in a clinical trial. A phase one...
Blinding
Clinical Trials: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioequivalence studies: Biowaivers